NET SALES +15% JANUARY - SEPTEMBER 2014

INTERIM REPORT JANUARY - SEPTEMBER 2014.

For the July –September period         

  • Net sales for the period rose to SEK 32.4 million (28.4).

  • Operating income (EBIT) for the period was SEK 7.3 million (2.8).

  • Operating margin for the period rose to 22 percent (9).

  • Earnings after tax for the period was SEK 6.4 million (-0.3).

  • Earnings per share for the period, basic and diluted, were SEK 0.05 (0.00).

For the January – September period

  • Net sales for the period rose to SEK 94.5 million (82.4).

  • Operating income (EBIT) for the period was SEK 13.4 million (7.4).

  • Operating margin for the period was 14 percent (8).

  • Earnings after tax for the period was SEK 8.0 million (2.1).

  • Earnings per share for the period, basic and diluted, were SEK 0.06 (0.03).

President and CEO Anders Karlsson’s commentary on the third quarter 2014:
 
”We’re seeing revenue growth of almost 15 percent for the current year and are now reporting an upswing in sales for the sixth consecutive quarter. During the year, we've seen growth in our core markets, both in Europe and the USA, with growth also spurred by increased sales on new markets. We’re pleased to report positive developments in operating profit, with operating margins at cumulative EBIT levels for the year of 14 percent. In the third quarter, we intensified development work on a new real-time PCR product, which we regard as an important strategic step for our typing product portfolio going forward.”

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: anders.karlsson@allenex.se
Yvonne
Axelsson, CFO Allenex AB, and ph.: +468-508 939 72, e-mail: yvonne.axelsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 27, 2014, at 08.30 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the Allenex group.

Tags:

About Us

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). The company’s largest owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See www.linkmed.se for more information.

Subscribe

Documents & Links